Dendrite Clinical Systems is delighted to report that our Managing Director, Dr Peter Walton, has published a chapter discussing the value of clinical registries in new publication on Laparoscopic Sleeve Gastrectomy (LSG). In his Chapter, Dr Peter Walton outlines value of national bariatric registries and their capability to deliver evidence on a global basis, as well as providing some practical perspectives on best practice when setting out to start a national registry and how to keep a good registry going.
Dendrite Clinical Systems and the Institute for Health Research (IGES) in Berlin, Germany, have initiated the Outpatient Treatment of COVID-19 Infections (ABC-19) study, to record data on the treatment of COVID-19 patients and discover more about the outpatient course of the disease, the individual risk factors of patients that contribute to severe COVID-19 courses and the procedures of general practitioners (GPs).
Researchers at the University College London and University College London Hospitals NHS Foundation Trust), London, UK, have reported that the vast majority of participants with new onset loss of smell were positive for COVID19, and this acute loss of sense of smell needs to be considered globally as a criterion for self-isolation, testing and contact tracing in order to contain the spread of COVID-19.
Dendrite Clinical Systems’ innovative “Intellect Web” software has been chosen by an international group of 17 leading diabetes experts from the multidisciplinary Diabetes Surgery Summit (DSS), as the platform on which the CoviDiab project will establish a Global Registry to collect new cases of diabetes in patients with COVID-19.
Real World Evidence
Dendrite Clinical Systems is a global leader in the area of clinical registries with an extensive experience in the field of Real World Evidence studies.
Real World Evidence goes beyond traditional controlled clinical trials. Pharmaceutical and medical device companies can use Real World Evidence data to inform stakeholders about a product's use, treatment patterns (standards of care), benefits and cost effectiveness to gain and defend market access, inform the design of products and trials and transform their relationships with clinicians from a supplier to a collaborator.
Large scale Real World Evidence data has not been available until recently – this is a major opportunity to demonstrate the value of your products. All of the major pharmaceutical companies have recently initiated Real World Evidence projects to inform product development and/or commercial decisions. Post market research has been the only growing area in the clinical research field in recent years. Indeed, if pharmaceutical and medical device companies do not take the initiative and lead the development of compelling real world cost-effectiveness arguments, regulatory agencies will create their own potentially unfavourable product narratives of which we have seen multiple examples already.
While there may be various sources of real world clinical information (such as Electronic Patient Record systems), implementation experience has proven that this information is mostly sporadic, incomplete and difficult to reconcile and analyse, particularly on a large scale. Clinical registries have proven to be the main source of scientifically robust large scale Real World Evidence to date.
Our customer dedication and delivery track record is impeccable. We would be delighted to work with you to help you design and support your Real World Evidence project.
Please contact us to discuss your Real World Evidence project:
Email: rwe@e-dendrite.com
Phone: +44 20 8949 8999 (Dr Alexey Brovko)
